Camber Pharmaceuticals Inc.
FDA Regulatory Profile
Summary
- Total Recalls
- 5 (1 Class I)
- 510(k) Clearances
- 0
- Inspections
- 2
- Compliance Actions
- 0
Recent Recalls
| Number | Class | Product | Date |
|---|
| D-0567-2023 | Class I | Atovaquone Oral Suspension USP, 750 mg/5 mL, Packaged in 210 mL bottle, Manufactured for: Camber Pha | March 13, 2023 |
| D-0094-2023 | Class III | Lacosamide Oral Solution, USP, CV, 10mg/mL, packaged in 200 mL bottle, Rx Only, Manufactured for: Ca | December 6, 2022 |
| D-1041-2019 | Class II | Losartan Potassium Tablets USP, 25 mg, Rx only, a) 90 count (NDC 31722-700-90), b) 500 count (NDC 31 | February 28, 2019 |
| D-1043-2019 | Class II | Losartan Potassium Tablets USP, 100 mg, Rx only, a) 30 count (NDC 31722-702-30), b) 90 count (NDC 31 | February 28, 2019 |
| D-1042-2019 | Class II | Losartan Potassium Tablets USP, 50 mg, Rx only, a) 30 count (NDC 31722-701-30), b) 90 count (NDC 317 | February 28, 2019 |